Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans

Michael A. Eller1,2,3, Kim G. Blom3, Veronica D. Gonzalez3, Leigh Anne Eller1,2, Prossy Naluyima1, Oliver Laeyendecker4,5, Thomas C. Quinn4,5, Noah Kiwanuka6,7, David Serwadda6,7, Nelson K. Sewankambo7,8, Boonrat Tassaneetrithep2,9, Maria J. Wawer7,10, Ronald H. Gray7,11, Mary A. Marovich2, Nelson L. Michael2, Mark S. de Souza2,12, Fred Wabwire-Mangen1,6, Merlin L. Robb2, Jeffrey R. Currier2, Johan K. Sandberg3*

1 Makerere University Walter Reed Project, Kampala, Uganda, 2 U. S. Military HIV Research Program, Rockville, Maryland, United States of America, 3 Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, 4 National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 5 Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America, 6 School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda, 7 Rakai Health Sciences Program, Uganda Virus Research Institute, Entebbe, Uganda, 8 Faculty of Medicine, Makerere University College of Health Sciences, Kampala, Uganda, 9 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 10 Columbia University Mailman School of Public Health, New York, New York, United States of America, 11 Johns Hopkins Center for Global Health, Baltimore, Maryland, United States of America, 12 Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

Abstract

HIV-1 disease progression is associated with persistent immune activation. However, the nature of this association is incompletely understood. Here, we investigated immune activation in the CD4 T cell compartment of chronically HIV-1 infected individuals from Rakai, Uganda. Levels of CD4 T cell activation, assessed as co-expression of PD-1, CD38 and HLA-DR, correlated directly to viral load and inversely to CD4 count. Deeper characterization of these cells indicated an effector memory phenotype with relatively frequent expression of Ki67 despite their PD-1 expression, and levels of these cells were inversely associated with FoxP3+ regulatory T cells. We therefore use the term deregulated effector memory (DEM) cells to describe them. CD4 T cells with a DEM phenotype could be generated by antigen stimulation of recall responses in vitro. Responses against HIV-1 and CMV antigens were enriched among the DEM CD4 T cells in patients, and the diverse Vβ repertoire of DEM CD4 T cells suggested they include diverse antigen-specificities. Furthermore, the levels of DEM CD4 T cells correlated directly to soluble CD14 (sCD14) and IL-6, markers of innate immune activation, in plasma. The size of the activated DEM CD4 T cell subset was predictive of the rate of disease progression, whereas IL-6 was only weakly predictive and sCD14 was not predictive. Taken together, these results are consistent with a model where systemic innate immune activation and chronic antigen stimulation of adaptive T cell responses both play important roles in driving pathological CD4 T cell immune activation in HIV-1 disease.

Citation: Eller MA, Blom KG, Gonzalez VD, Eller LA, Naluyima P, et al. (2011) Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans. PLoS ONE 6(4): e18779. doi:10.1371/journal.pone.0018779

Editor: Lichomwawo C. Ndhlovu, University of California San Francisco, United States of America

Received January 28, 2011; Accepted March 9, 2011; Published April 19, 2011

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: Primary support was provided by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U. S. Department of Defense. Data collection was supported, in part, by grants R01 AI34826 and R01 AI34265 from the National Institute of Allergy and Infectious Diseases (NIAID); grant SP01HD06826 from the National Institute of Child and Health Development; grant SD3TW00010 from the Fogarty Foundation and NIH grant R01 AI34826. Additional support was provided by the Swedish Research Council, the Swedish Cancer Foundation, the Stockholm County Council, Karolinska Institutet, and the Division of Intramural Research, NIAID, NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: johan.sandberg@ki.se

Introduction

HIV-1 disease progression is associated with chronic activation of the immune system [1,2,3,4,5,6,7,8] [reviewed in [9,10]], but the mechanisms involved remain incompletely understood. Unraveling the causes, interactions, and mechanisms underlying immune activation is thus central to the understanding of HIV pathogenesis and one of the major “roadblocks” in HIV research [11]. One proposed cause of systemic immune activation is microbial product translocation across a gut barrier damaged by intense HIV replication [12,13]. Brenchley et al. found that lipopolysaccharide (LPS) and soluble CD14 (sCD14), thought to be correlative markers of microbial translocation, in plasma were associated with CD8 T cell activation in chronic HIV-1 infection [12]. A role for microbial translocation is supported by findings in natural SIV infection of African green monkeys and sooty mangabeys [14,15,16]. However, high levels of LPS in rhesus monkeys may not predict faster disease progression [17]. A second proposed cause behind chronic activation is direct innate recognition of viral RNA and subsequent activation of the type I interferon (IFN) response, and this is also supported by data from natural hosts of SIV, which exhibit a lower and less sustained
response to viral RNA [18,19,20]. Interestingly, gene-expression profiling of monocytes from HIV-1 infected patients suggested that IFNγ may be an important factor in the activation of these cells [21]. A third possible cause of activation in the T cell compartment is direct TCR-mediated recognition of antigens, and fourth possibility is bystander activation, which may be driven by the aforementioned mechanisms or have other causes [22]. It is important to recognize that these four different suggested mechanisms are not mutually exclusive.

Immune cell exhaustion plays a role in loss of control of HIV-1 viremia. Programmed death 1 (PD-1, or CD279), is a negative regulator of T cell activation [23]. The association between PD-1 expression and poor function of HIV-specific T cells and aspects of HIV disease has been observed for CD8 T cells [24,25,26,27], and for CD4 T cells [28]. Blocking of the PD-1 pathway in vivo in macaques results in increased SIV-specific T cell function and longer survival of the animals [29,30]. In summary, uncontrolled activation combined with exhaustion and excessive negative feedback regulation contribute to a situation with poor immune control of HIV.

FoxP3+ regulatory T cells (Tregs) are important for maintaining immune tolerance and autoimmunity [31]. In HIV-1 infection, Tregs probably have a beneficial function by limiting the damage of immune activation [32,33,34,35]. However, loss of Tregs from blood may represent redistribution to lymphoid tissues where they might interfere with T cell control of HIV-1 replication [36,37]. The beneficial role of Tregs in HIV-1 disease is thus not entirely clear-cut. In this study, we investigated aspects of immune activation and immune regulation with the aim to better understand pathological immune activation in the CD4 T cell compartment of HIV-1 infected patients in sub-Saharan Africa, and to better understand relationships between CD4 T cell activation and possible causes of such activation.

Materials and Methods

Study cohort and samples

Study participants aged 15–49 years were enrolled in a prospective community-based cohort to assess the prevalence and incidence of HIV-1 infection in Rakai District, Uganda, from 1998 until 2004 (Table 1) [38,39,40]. Infected subjects were identified between 1997 and 2002 with continued annual follow up through 2008. The study was approved by institutional review boards in the US and Uganda: The institutional Review Boards of Uganda’s National Council for Science and Technology (UNCST) and the Uganda Virus Research Institute’s Science and Ethics Committee, as well as the Division of Human Subjects Protection at the Walter Reed Army Institute of Research. Written informed consent given by all participants, and written informed consent was obtained from the parent or legal guardian of those aged 17.

PBMC samples were isolated and cryopreserved as described [41], from 103 randomly selected HIV-1 sero-positive individuals and 40 community-matched sero-negative controls. No patients were on antiretroviral therapy. HIV-1 testing was performed as described [40]. Positive samples were subjected to the Amplicor HIV-1 Monitor test, version 1.5 (Roche Diagnostics, Indianapolis, IN).

Flow cytometry and mAbs

Cryopreserved specimens were thawed and washed, and counts and viability assessed on the Guava PCA (Guava Technologies, Hayward, CA), using Guava ViaCount reagent. Cells washed with PBS/BSA buffer, and stained at 4°C for 30 min in 96-well V-bottom plates in the dark. mAbs used in flow cytometry; anti-HLA-DR FITC or V450, IgG2a FITC, anti-PD-1 PE or IgG1 PE, anti-CD5 PerCP-Cy5.5 or APC-H7, anti-CCR7 PE-Cy7, anti-CD8 PE-Cy7 or PE-TR or Qdots 605, anti-CD38 APC or IgG1 APC, anti-CD4 Pacific Blue (PB) (all from BD Biosciences, San Jose, CA), and Aqua Live/Dead Stain (Invitrogen, Carlsbad, CA). The anti-PD-1 PE (clone EH12) was a kind gift from Maria Jaimes at BD Biosciences. Anti-CD19 PE-Cy5, and anti-CD45RO eF650NC were from eBioscience (San Diego, CA). Anti-PD-1 PE (clone EH12) was a kind gift from Maria Jaimes at BD Biosciences. Anti-CD19 PE-Cy5, and anti-CD45RO eF650NC were from eBioscience (San Diego, CA), and anti-CD28 PerCP-Cy5.5 was from BioLegend (San Diego, CA). Anti-CD4 Qdot605, and anti-CD14 PE-Cy5 were from Invitrogen. Anti-CD4 ECD was from Beckman Coulter (Brea, CA). For assessment of Ki67 expression, cells were fixed and permeabilized with eBioscience fix/perm for 60 min at 4°C and stained with anti-Ki67 FITC (BD Biosciences) for 30 min. Tregs were identified using anti-CD25 PE, anti-CD3 PerCP-Cy5.5, anti-CD127 APC, and anti-CD4 PB (all from BD Biosciences). Samples were washed, permeabilized and fixed using a kit optimized for FoxP3 staining (eBioscience, San Diego, CA), and stained with anti-FoxP3 Alexa Fluor 488 (BioLegend San Diego, CA). Flow cytometry data was acquired using a BD LSR II instrument or a BD FACS Canto II instrument (BD

Table 1. Study population descriptive statistics.

|                        | HIV-1 negative | HIV-1 positive |
|------------------------|----------------|---------------|
| Subjects, no.          | 40             | 103           |
| Female, no. (%)        | 20 (50%)       | 65 (63%)      |
| Male, no. (%)          | 20 (50%)       | 38 (37%)      |
| Age, median years (range) | 29 (20–42)   | 30 (17–53)    |
| Time from sero-conversion, median days (range) | 2013 (22–2284) |               |
| Viral load, median copies/ml (range) | 35,828 (528–1,685,638) |               |
| CD4 absolute count, median cells/μl (range) | 513 (1–1385) |               |
| HIV-1 subtype A, no. (%) | NA            | 35 (34%)     |
| HIV-1 subtype D, no. (%) | NA            | 68 (66%)     |
| Hepatitis B virus, no. (%) | 3 (8%)        | 8 (8%)       |
| Syphilis, no. (%)      | 3 (8%)         | 9 (9%)        |

NA indicates not applicable.

doi:10.1371/journal.pone.0018779.t001
CD4 T Cell Activation in HIV Disease

Results

Activated CD4 T cells with co-ordinate expression of HLA-DR, CD38, and PD-1 are deregulated effector memory cells and elevated in chronically HIV-1 infected patients in Rakai, Uganda

HIV-1 negative (n = 40) and HIV-1 positive (n = 103) individuals from a cohort in Rakai, Uganda, were chosen to study CD4 T cell activation in untreated HIV-1 infection (Table 1). Activated CD4 T cells expressing CD38 and HLA-DR were identified by flow cytometry (Figure 1A). These cells were largely positive for PD-1, suggesting an exhausted phenotype. The CD38+ HLA-DR+PD-1+ CD4 T cell subset was directly correlated with viral load (r = 0.549, P < 0.001) (Figure 1B). To further characterize the PD-1+HLA-DR+CD38+CD4 T cell subset, we analyzed their expression of CD435RO, CCR7, CD28, and Ki67. These cells were largely CD435RO+, CD28+, and negative or dim for CCR7. In addition, a proportion expressed the proliferation marker Ki67 (Figure 1C). This expression pattern is consistent with an effector memory profile that retains the proliferative capacity, despite the expression of PD-1.

Regulatory activity mediated by Tregs is important to limit inappropriate or persistent immune activation [31]. The CD4+CD25+CD127-FoxP3+ Treg compartment was reduced in HIV-1 infected subjects (Figure 2A), but the Treg levels did not correlate with the CD4 count (Figure 2B), or viral load (Figure 2C). However, there was an inverse relationship between FoxP3+ Tregs and PD-1+HLA-DR+CD38+CD4 T cells (r = −0.444, P < 0.001) (Figure 2D). The Ki67+ effector memory phenotype of the PD-1+HLA-DR+CD38+CD4 T cells, and the association between these cells and the decline in the Treg compartment, together supports a model in which these cells are deregulated effector memory (DEM) cells.

Correlates between DEM CD4 T cell expansion and HIV-1 disease

We next investigated associations between immune activation in CD4 T cells and aspects of HIV-1 disease in this cohort. The size of the DEM CD4 T cell subset was directly correlated with viral load (r = 0.549, P < 0.001) (Figure 3A), and inversely correlated with CD4 count (r = −0.603, P < 0.001) (Figure 3B). Next, the ability to predict progression to AIDS in this cohort using the DEM CD4 T cell phenotype was assessed. AIDS was defined as CD4 counts below 250 cells/μl. Patients were divided into two groups for having levels of DEM CD4 T cells above or below the median (6%) (Figure 3C). Values below the median overlapped with the range observed in uninfected subjects. Patients with levels above 6% of CD4 T cells were more likely to progress to AIDS (log-rank P = 0.001, HR 0.336, 95% CI = 0.173-0.653). Notably, the two groups with high and low levels of DEM CD4 T cells did not differ significantly in their estimated time since infection (data not shown). Thus, the DEM phenotype identifies a state of pathological immune activation in the CD4 T cell compartment which is associated with HIV-1 disease progression.

Associations between measures of HIV disease progression and soluble CD14 and IL-6, measures of innate immune activation, in plasma

CD14 is released from monocytes upon activation, and soluble CD14 (sCD14) in plasma can be used as a marker of such activation in response to innate stimuli [12,42]. sCD14 was elevated in HIV-1 infected subjects as compared to uninfected...
controls (P<0.001) (Figure 4A), and CD4 counts in infected subjects correlated inversely with sCD14 in plasma (r = -0.482, P<0.001) (Figure 4B). There was also a weak positive correlation between sCD14 levels and viral load (r = 0.282, P = 0.004) (Figure 4C). Importantly, however, subjects with high and low sCD14 levels did not differ in their AIDS-free survival during clinical follow-up (Figure 4D). Similarly, patients with Treg levels above or below the median percentage did not differ in their AIDS-free survival (data not shown).

IL-1β, IL-12p70, TNFα, IL-10, IL-6 and IL-8 were measured in plasma from HIV-1 infected and uninfected subjects, and IL-6 and IL-8 were found to be significantly elevated in the infected group (Figure 4E and data not shown). However, only IL-6 showed an inverse correlation with CD4 counts (r = -0.394, P<0.001) (Figure 4F), and a weak positive association with viral load (r = 0.278, P = 0.005) (Figure 4G). In contrast to the pattern with sCD14, having above the median level of IL-6 in plasma was a significant predictor of faster disease progression (log-rank P = 0.023, HR 0.462, 95% CI = 0.238-0.900) (Figure 4H). In summary, measures of innate immune activation, sCD14 and IL-6, show a degree of association with HIV-1 disease. However, these associations are weaker than those observed between CD4 count, viral load, AIDS-free survival, and the size of the DEM CD4 T cell population.

**Figure 1. PD-1, HLA-DR, and CD38 together identify an effector memory CD4 T cell subset elevated in HIV-1 infection.**

(A) Identification of CD4 T cells co-expressing PD-1, HLA-DR and CD38 in HIV-1 infected and uninfected subjects. (B) Box and whisker plots showing the median and 10–90 percentile percentage of CD38, HLA-DR and PD-1 triple-expression in CD4 T cells in HIV negative (n = 40) and HIV positive (n = 103) subjects. (C) In order to assess the phenotype of the activated CD4 T cells, PBMC were analyzed by flow cytometry for the expression of CD45RO, CCR7, CD28, and Ki67. Filled line represents CD4 cells triple-positive for CD38, HLA-DR, and PD-1, while dashed line represents data from the overall CD4 compartment and empty filled line is the fluorescence minus one (FMO) control for that channel.

doi:10.1371/journal.pone.0018779.g001

Analysis of relationships between the DEM CD4 T cell expansion and measures of innate immune activation

These data behooved us to next search for association between the DEM CD4 T cell population, Tregs, sCD14 levels, and IL-6
levels. Interestingly, the size of the DEM CD4 T cell population was directly associated with levels of sCD14 (r = 0.443, P < 0.001) (Figure 5A), and levels of IL-6 (r = 0.303, P < 0.001) (Figure 5B). The two measures of innate immune activation, IL-6 and sCD14, were weakly correlated (r = 0.323, P = 0.001) (Figure 5C). Tregs showed an inverse correlation with DEM CD4 T cells (r = -0.444, P < 0.001), but no significant correlation with CD4 count and viral load (Figure 2). Similarly, there was no correlation between Treg levels, and levels of sCD14 or IL-6 (Figure 5D and E, respectively). Thus, DEM CD4 T cell expansion is associated with both innate immune activation and decline in circulating Tregs. However, innate immune activation and changes in Tregs show no apparent association.

Expansion of DEM CD4 T cells can be driven by antigen in vitro

We next investigated factors that might be involved in driving the expansion of PD-1+HLA-DR+CD38+ CD4 T cells. To begin to address the hypothesis that high antigen loads may drive this population, we first stimulated PBMC from healthy donors with a set of different recall antigens, mitogens and superantigen (Figure 6A). Several of the stimuli, in particular CMV and Candida antigens, provoked significant expansions of triple-positive CD4 T cells (Figure 6B).

In a second approach, we assessed CD4 T cell responses in the HIV-1 infected patients against CMV, HIV and SEB (Figure 6C). Responses against all these antigens were measured by intracellular co-staining for both IFNγ and TNFα, and found to be enriched in the DEM CD4 T cells as compared to the overall CD4 compartment. These data collectively indicate that the DEM CD4 T cell phenotype may be driven by antigen stimulation.

DEM CD4 T cells display a non-biased VBβ distribution

Enrichment of antigen-specific responses in the DEM CD4 T cells is consistent with an antigen-driven expansion of these cells. Nevertheless, the percentages of antigen-specific responses in the DEM CD4 T cells were modest. We therefore next investigated the TCR VBβ distribution of these cells, where a strongly biased VBβ distribution would be consistent with a narrowly antigen-driven expansion. Surprisingly, the DEM CD4 T cells displayed a diverse VBβ distribution very similar to the overall CD4 T cell compartment (Figure 6D). Taken together, these results support a model where a broad array of antigens support the generation of diverse DEM CD4 T cells in the context of the innate immune activation milieu that persists in chronically HIV-1 infected individuals.

Discussion

In the present study, we aimed to better understand persistent immune activation in the CD4 T cell compartment of HIV-1 infected patients in rural Uganda, and to investigate relationships...
with possible causes of such activation. The results suggest that pathologically activated CD4 T cells have a Ki67+ effector memory phenotype, and because they are activated despite their expression of PD-1, and correlate inversely with FoxP3+ Treg levels, we use the term deregulated effector memory (DEM) cells to describe them.

Monocyte activation in response to microbial material results in the release of sCD14, which is seen at elevated levels in infected

Figure 4. Associations between sCD14 and IL-6 levels in plasma and measures of HIV-1 disease progression. (A) Box and whisker plot showing sCD14 levels in plasma from HIV-1 infected (n = 103) and HIV-1 uninfected (n = 40) subjects. Spearman rank correlations between sCD14 in plasma and (B) CD4 absolute T cells counts, and (C) viral load. (D) Kaplan-Meier analysis comparing the time to AIDS. HIV-1 positive subjects with sCD14 levels above and below the median (1939 ng/ml) were not statistically different (Log-rank P = 0.185, Hazard Ratio (HR) 0.631, 95% CI = 0.319 to 1.247). (E) Box and whisker plot showing IL-6 levels in plasma from HIV-1 infected (n = 103) and HIV-1 uninfected (n = 40) subjects. Spearman rank correlations between IL-6 in plasma and (F) CD4 absolute T cells counts and (G) viral load. (H) Kaplan-Meier analysis comparing the time to AIDS. HIV-1 positive subjects with IL-6 levels above the median (3.2 pg/ml) more likely to advance to AIDS (Log-rank P = 0.023, HR 0.462, 95% CI = 0.238–0.900).

doi:10.1371/journal.pone.0018779.g004

Figure 5. sCD14 and IL-6 correlate with levels of deregulated effector memory CD4 T cells, but not with Tregs. (A) Spearman rank correlation between sCD14 in plasma and CD38, HLA-DR and PD-1 triple-positive CD4 T cells in blood. (B) Spearman rank correlation between IL-6 in plasma and CD38, HLA-DR and PD-1 triple-positive CD4 T cells. (C) Spearman rank correlation between IL-6 and sCD14 in plasma. (D) Spearman rank correlation between Tregs and IL-6. (E) Spearman rank correlation between Tregs and sCD14 levels.

doi:10.1371/journal.pone.0018779.g005
Figure 6. CD38+HLA-DR+PD-1+ cells can be driven by antigen in vitro, but display a non-biased Vβ distribution in vivo. (A) Experiments were conducted to assess the ability to generate the combined expression of CD38, HLA-DR, and PD-1 on CD4 T cells after three days of mitogen stimulation, or six days of antigen or superantigen stimulation of PBMC from four healthy donors. Bars represent mean and standard error of the mean. (B) Example PD-1 expression flow cytometry histogram and contour plot for CD38 and HLA-DR expression on CD4 T cells from one CMV non-responder (top panels), and one CMV responder after six days of stimulation with CMV lysate. (C) In order to characterize the prevalence of antigen...
subjects [12,42]. We found that sCD14 correlated inversely with CD4 counts and directly with DEM CD4 T cell levels. sCD14 also correlated positively, albeit weakly, with viral load. Notably, however, groups with high and low levels of sCD14 did not differ in their pace of disease progression during clinical follow-up. IL-6 is released in response to activation of innate cells, including monocytes, and displayed correlations with CD4 counts and DEM CD4 T cells similar to those of sCD14. Also in similarity with sCD14, the correlation with viral load was very weak. However, in contrast to sCD14, patients with high and low levels of IL-6 differed in their rate of progression to AIDS during clinical follow-up. One might therefore speculate that IL-6 is more likely than sCD14 to indicate pathogenic processes in the innate immune system during chronic untreated HIV-1 infection. Treg levels correlated inversely with DEM CD4 T cells, but showed no correlation with CD4 count, viral load, IL-6 or sCD14. Changes in Treg percentages thus appear to be primarily associated with the activated DEM CD4 T cell expansion, and less so to the other measures of disease.

We observed that the DEM CD4 T cell phenotype can be driven in vitro by stimulation of healthy donor PBMC with recall antigens for six days. In particular, stimulation with CMV and Candida antigens resulted in effective expansion of such cells. In addition, there was an enrichment of HIV-specific and CMV-specific cells in the DEM CD4 T cell subset in patients. These observations support a model where the DEM cell expansion is at least partly antigen-driven. We were therefore surprised to find that the TCR Vβ distribution was not significantly different between these cells and the rest of the CD4 compartment in HIV-1 infected subjects. If the DEM CD4 T cells were strongly driven by a few antigens, then one would expect a biased Vβ distribution. Since this was not the case, it seems likely that the expanded DEM CD4 T cells are specific for a diverse array of antigens from HIV, CMV, and other pathogens. We therefore suggest a model in which the accumulation of DEM CD4 T cells is the result of antigen-driven expansion under conditions when the immune system is exposed to microbial material, including components of HIV, driving innate immune activation.

The correlation between levels of IL-6 and DEM CD4 T cells, albeit weak, initially suggested that this cytokine might be involved in the generation or maintenance of these cells [43]. HIV-1 infection has long been associated with increased levels of IL-6 [44,45], and IL-6 can be produced by monocytes in response to both LPS and the HIV-1 accessory protein Vpr [46], suggesting that both viral and bacterial antigens could contribute to the increased levels of this inflammatory cytokine. In the present study, blocking of IL-6 or IL-6R or addition of exogenous IL-6 to cultures had no measurable effect (data not shown). This does not contradict a possible role of IL-6 during long-term exposure. Another factor of interest, according to the hypothesis that excessive TLR7/9 signaling in response to HIV RNA underlies persistent immune activation, is type I IFNs [18,19,20]. However, similar to the results with IL-6, we observed no effect by addition of IFNα in cultures (data not shown). Of note, IFNα treatment of HIV patients on successful ART co-infected with hepatitis C virus was previously observed to reduce immune activation [47].

Similarly, we observed no effect on DEM cell expansion by adding whole inactivated HIV to short-term in vitro cultures (data not shown). Again, these observations do not contradict a pathogenic contribution of type I IFNs in vivo, in particular as a co-factor working together with other causes of activation.

In a previously published longitudinal study based on this Ugandan cohort, soluble markers of innate immune activation in plasma did not change over the course of HIV disease progression [40]. The relationships between microbial translocation, chronic activation of innate and adaptive immune cells, levels of cytokines and other markers in plasma, and HIV disease progression are thus very complex. However, the present study supports an association between innate immune activation and expansion of the DEM CD4 T cells. This CD4 T cell phenotype may identify the cells, which are activated by chronic antigen stimulation in the context of innate immune system activation by microbial components. Such material may be derived from microbial translocation, as well as from HIV virions. Here, levels of DEM CD4 T cells correlated directly to HIV viral load, possibly supporting a role for viral proteins or RNA in the expansion of these cells.

The DEM CD4 T cells display a CD45RO+CCR7- effector memory phenotype, and they express Ki67 at a higher rate than the overall CD4 T cell compartment. The relatively frequent expression of Ki67 suggests that this is an actively proliferating cell subset despite the expression of PD-1, which is a negative regulator of TCR signaling. The question arises as to what extent PD-1 is a strong inhibitory receptor in CD4 T cells in vivo. One possibility is that the negative signals mediated by PD-1 are counter balanced by co-stimulation via CD28 [49].

The data presented in this paper are consistent with a model where continuous exposure to microbial material, including components of HIV, creates conditions permissive to the expansion pathologically activated CD4 T cells with the DEM phenotype. The accumulation of DEM CD4 T cells may result from antigen-driven expansion under conditions of persistent innate immune activation. Future studies to examine the mediators of pathogenic T cell activation are needed to allow the development of targeted therapies to alleviate activation and, possibly, slow disease progression.

Acknowledgments
The authors wish to acknowledge the Rakai Community Cohort Study volunteers for their participation. We would also like to thank Andy Reid for critical review of this manuscript. Disclaimer: The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.

Author Contributions
Conceived and designed the experiments: MAE JRC JKS. Performed the experiments: MAE KGB VDG LAE PN BT. Analyzed the data: MAE JRC JKS. Contributed reagents/materials/analysis tools: OL TCQ NK DS NKS MJW RHG MAM NLM MSS FWM MLR. Wrote the paper: MAE JKS.
References

1. Giorgi JV, Detels R (1989) T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol 52: 10–19.
2. Hazenberg MD, Otto SA, van Benhmen BH, Roos MT, Cousinaho RA, et al. (2003) Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 1881–1888.
3. Giorgi JV, Haltin LE, McKeating JA, Johnson TD, Owens B, et al. (1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859–870.
4. Giorgi JV, Lyles RH, Marot JL, Yamashita TE, Mellors JW, et al. (2002) Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 29: 346–355.
5. Eggens MP, Barraghare B, Okello M, Mutyala S, Jones N, et al. (2003) T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 191: 694–701.
6. Barry SM, Johnson MA, Janosky G (2003) Increased proportions of activated and proliferating memory CD8+ T lymphocytes in both blood and lung are associated with blood HIV viral load. J Acquir Immune Defic Syndr 34: 351–357.
7. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T cell changes independent of viral load. Blood 104: 942–947.
8. Hunt PW, Brenchley J, Sinclair E, McEwan JM, Roland M, et al. (2008) Relationship between CD4+ T cell count and HIV-1 viremia increases over time. J Infect Dis 197: 126–131.
9. Douek DC, Roederer M, Koup RA (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471–484.
10. Gonzalez VD, Landay AL, Sandberg JK (2010) Innate immunity and chronic human immunodeficiency virus infection: lessons from balance. J Immunol 184: 125–129.
11. Thomas C (2009) Roadblocks in HIV research: five questions. Nat Med 15: 855–859.
12. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365–1371.
13. Nazli A, Chan O, Dobson-Belave WN, Ouellet M, Tremblay MJ, et al. (2010) Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 6: e1000352.
14. Sodaor DL, Allan JS, Apetrei C, Pandrea I, Faye A, et al. (2005) Shorter survival in advanced human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T cell activation. J Virol 82: 8307–8315.
15. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in immune regulation. Annu Rev Med 59: 471–484.
16. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, et al. (2005) Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. J Virol 80: 1082–1091.
17. Sodora DL, Brenchley JM, Price DA, Douek DC, et al. (2009) Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 15: 861–865.
18. Kornfeld C, Pandrea I, Panzara L, Faye A, Onanga R, et al. (2005) Antinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 115: 1082–1091.
19. Ndhlovu LC, Koon CK, Jonker JM, Sonneveld PA, Boshoff C, et al. (2008) Preservation of memory CD8+ T cell function in HIV-1-infected individuals. Proc Natl Acad Sci U S A 105: 13–18.
20. Ndhlovu LC, Loo CP, Spotts G, Nisonoff A, Hefte J, et al. (2008) Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology 124: 277–293.
21. Oka S, Hasegawa K, Kudo K, Muro M, Kornfeld C, et al. (2005) CD28+CD4+ and CD8+ T cell responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331–343.
22. Douek DC, Roederer M, Koup RA (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471–484.
23. Kinter AL, Brenchley J, Sinclair E, McCune JM, Roland M, et al. (2006) Higher HIV-1 Incidence and Genetic Complexity Along Main Roads in Rakai District, Uganda. J Acquir Immune Defic Syndr 43: 449–453.
24. Harris M, Serwadda D, Newambo NM, Kim B, Kagezi G, et al. (2002) Among 46 near full-length HIV Type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses 18: 1201–1209.
25. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, et al. (2009) Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4+ and CD8+ T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331–343.
26. Eggens MP, Barraghare B, Jones N, Okello M, Mutyala S, et al. (2005) Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 174: 4407–4414.
27. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in immune regulation. Annu Rev Med 59: 471–484.
28. D’Onofrio M, Fornerot AP, Mark DG, Boneau N, Dillon S, et al. (2007) Programmed death-1 expression on HIV-specific CD4+ T cells depends on viral replication and associated with T cell dysfunction. J Immunol 179: 1979–1987.
29. Velu V, Tianzhi K, Zhu B, Hussian S, Padelova A, et al. (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 295–301.
30. Onsluomo N, Rogers K, Mayne AE, Pattanapanyasat K, Mori K, et al. (2008) Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology 124: 277–293.
31. Oka S, Hasegawa K, Kudo K, Muro M, Kornfeld C, et al. (2005) CD28+CD4+ and CD8+ T cell responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331–343.
32. Douek DC, Roederer M, Koup RA (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471–484.
33. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, et al. (2009) Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4+ and CD8+ T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331–343.
34. Oka S, Hasegawa K, Kudo K, Muro M, Kornfeld C, et al. (2005) CD28+CD4+ and CD8+ T cell responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331–343.